20240018199. MENTSH ANALOGS AS THERAPEUTICS FOR DIABETES, OBESITY, AND THEIR ASSOCIATED DISEASES AND COMPLICATIONS simplified abstract (UNIVERSITY OF SOUTHERN CALIFORNIA)

MENTSH ANALOGS AS THERAPEUTICS FOR DIABETES, OBESITY, AND THEIR ASSOCIATED DISEASES AND COMPLICATIONS

Organization Name

UNIVERSITY OF SOUTHERN CALIFORNIA

Inventor(s)

Pinchas Cohen of Los Angeles CA (US)

Kelvin Yen of Los Angeles CA (US)

MENTSH ANALOGS AS THERAPEUTICS FOR DIABETES, OBESITY, AND THEIR ASSOCIATED DISEASES AND COMPLICATIONS - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240018199 titled 'MENTSH ANALOGS AS THERAPEUTICS FOR DIABETES, OBESITY, AND THEIR ASSOCIATED DISEASES AND COMPLICATIONS

Simplified Explanation

The abstract describes a novel mitochondrial-encoded open reading frame that produces a new mitochondrial peptide. A specific small nucleotide polymorphism disrupts the expression of this peptide, which is correlated with an increase in obesity and diabetes in certain ethnic populations. In vitro administration of the peptide improves insulin secretion, decreases fat accumulation, and improves glucose uptake in muscle cells. Antibodies against the peptide can be used for detecting peptide deficiency and SNP detection for diagnostic purposes. In vivo studies show that administration of the peptide improves glucose tolerance and decreases bodyweight, providing a new therapeutic avenue for diabetes and obesity treatment. Synthetic analogs of the peptide can enhance or abrogate its activity.

• Novel mitochondrial-encoded open reading frame produces a new mitochondrial peptide
• Specific small nucleotide polymorphism disrupts peptide expression
• Correlated with increased obesity and diabetes in certain ethnic populations
• In vitro administration of the peptide improves insulin secretion, decreases fat accumulation, and improves glucose uptake in muscle cells
• Antibodies against the peptide can be used for detecting peptide deficiency and SNP detection
• In vivo studies show improved glucose tolerance and decreased bodyweight with peptide administration
• Synthetic analogs of the peptide can enhance or abrogate its activity

Potential Applications

• Diabetes therapy
• Obesity therapy
• Diagnostic approaches for detecting peptide deficiency and SNP detection

Problems Solved

• Lack of effective diabetes therapies
• Limited options for obesity treatment
• Difficulties in detecting peptide deficiency and SNP detection

Benefits

• Improved insulin secretion and glucose uptake
• Decreased fat accumulation and bodyweight
• New therapeutic avenue for diabetes and obesity treatment
• Diagnostic tool for detecting peptide deficiency and SNP detection

Original Abstract Submitted

described herein is a novel, mitochondrial encoded, open reading frame, that leads to the production of a new mitochondrial peptide. residing within the nd-two subunit, a specific small nucleotide polymorphism disrupts expression of this mitochondrial peptide, and is correlated with an increase in obesity and diabetes, particularly in certain ethnic populations. in vitro administration of the peptide increases insulin secretion, decreases fat accumulation and improves glucose uptake in muscle cell. antibodies generated against the peptide can be used for detecting peptide deficiency, in addition to snp detection, supporting diagnostic approaches. in vivo studies further revealed that administration of the peptide improves glucose tolerance, thereby providing a new therapeutic avenue for a novel diabetes therapy and decreases bodyweight, thus serving as a novel obesity therapy. generation of synthetic analogs further enhance or abrogated activity relative to the natural peptide.